HELICOBACTER-PYLORI, GASTRODUODENAL DISEASE, AND RECURRENT ABDOMINAL-PAIN IN CHILDREN

Citation
C. Macarthur et al., HELICOBACTER-PYLORI, GASTRODUODENAL DISEASE, AND RECURRENT ABDOMINAL-PAIN IN CHILDREN, JAMA, the journal of the American Medical Association, 273(9), 1995, pp. 729-734
Citations number
79
Categorie Soggetti
Medicine, General & Internal
ISSN journal
00987484
Volume
273
Issue
9
Year of publication
1995
Pages
729 - 734
Database
ISI
SICI code
0098-7484(1995)273:9<729:HGDARA>2.0.ZU;2-N
Abstract
Objective.-To assess the evidence for a cause-and-effect relationship between Helicobacter pylori infection and antral gastritis, peptic ulc er disease, and recurrent abdominal pain in children. Data Sources.-A MEDLINE search from January 1983 through July 1994 was used to identif y pertinent English-language publications. Current Contents and select ed specialty journals were searched manually. Editorials, reviews, cas e reports, abstracts, and letters to the editor were excluded. Study S election.-All studies in children (ie, 0 to 18 years) were included. D ata Extraction.-Hill's criteria for causal inference were used to dete rmine the strength of the evidence for a causal relationship. Data Syn thesis.-In total, 45 studies (case series, cross-sectional surveys, an d treatment trials) were retrieved. The rate ratio of antral gastritis in children with H pylori infection (compared with uninfected childre n) ranged from 1.9 to 71.0 (median, 4.6). The prevalence of H pylori i nfection in children with duodenal ulcer was high (range, 33% to 100%; median, 92%) compared with children with gastric ulcer (range, 11% to 75%; median, 25%). Prevalence rates of infection in children with rec urrent abdominal pain were inconsistent (range, 0% to 81%, median, 22% ), with lower rates in children meeting Apley's criteria (range, 0% to 9%; median, 6%). Conclusions.-There is strong evidence for an associa tion between H pylori infection and antral gastritis and duodenal ulce r disease in children; however, data from randomized, double-blind, pl acebo-controlled treatment trials are required. There is weak evidence for an association with gastric ulcer and weak or no evidence for an association with recurrent abdominal pain.